Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
44.00
+1.05 (+2.44%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
May 09, 2024
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.
Via
Chartmill
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
May 02, 2024
Via
Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
May 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial
April 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Recap: Corcept Therapeutics Q4 Earnings
February 15, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Earnings Preview: Corcept Therapeutics
February 14, 2024
Via
Benzinga
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
April 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
April 22, 2024
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the...
Via
Benzinga
Exposures
Product Safety
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
April 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
April 19, 2024
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.
Via
Chartmill
Despite its growth, NASDAQ:CORT remains within the realm of affordability.
January 03, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
Via
Chartmill
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
April 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
April 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
April 01, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
March 29, 2024
In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition.
Via
Chartmill
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.
March 07, 2024
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.
Via
Chartmill
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday?
February 16, 2024
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes.
Via
Benzinga
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
February 15, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
February 14, 2024
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
Via
Chartmill
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
February 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology
January 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
January 24, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued.
Via
Chartmill
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
January 22, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading...
Via
Benzinga
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
January 08, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Crude Oil Down 2%; Tesla Deliveries Top Estimates
January 02, 2024
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 02, 2024
Via
Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 02, 2024
Shares of Longboard Pharmaceuticals, Inc.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.